Robert Azelby has been named president and CEO of Alder BioPharmaceuticals (NASDAQ: [[ticker:ALDR]]). He will also join the Bothell, WA, company’s board of directors. After Azelby starts his new role on June 13, Alder’s interim CEO Paul Cleveland will resume his role as a member of the company’s board.
Alder’s founding CEO, Randy Schatzman, resigned from the company in a surprise announcement in March. The executive shakeup came as the company was working toward filing for FDA approval of eptinezumab, the company’s lead drug for migraine prevention. That filing was expected in the second half of this year. Alder has since updated its timeline with an early 2019 target for the FDA filing. Azelby is coming to Alder from Seattle-based Juno Therapeutics, where he was executive vice president and chief commercial officer. Before Juno, Azelby held various roles at Amgen (NASDAQ: [[ticker:AMGN]]).
